[go: up one dir, main page]

TR200102959T2 - İntegrin antagonistleri olarak ikame edilmiş bisiklik heteroaril bileşikleri - Google Patents

İntegrin antagonistleri olarak ikame edilmiş bisiklik heteroaril bileşikleri

Info

Publication number
TR200102959T2
TR200102959T2 TR2001/02959T TR200102959T TR200102959T2 TR 200102959 T2 TR200102959 T2 TR 200102959T2 TR 2001/02959 T TR2001/02959 T TR 2001/02959T TR 200102959 T TR200102959 T TR 200102959T TR 200102959 T2 TR200102959 T2 TR 200102959T2
Authority
TR
Turkey
Prior art keywords
bicyclic heteroaryl
compounds substituted
heteroaryl compounds
integrin antagonists
compounds
Prior art date
Application number
TR2001/02959T
Other languages
English (en)
Inventor
David Clark Edward
Robert Eastwood Paul
Victor Harris Neil
Mccarthy Clive
David Morley Andrew
Dennis Pickett Stephen
Original Assignee
Aventis Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9908355.2A external-priority patent/GB9908355D0/en
Application filed by Aventis Pharma Limited filed Critical Aventis Pharma Limited
Publication of TR200102959T2 publication Critical patent/TR200102959T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Metal-Oxide And Bipolar Metal-Oxide Semiconductor Integrated Circuits (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Semiconductor Integrated Circuits (AREA)

Abstract

Bulus R1Z1-Het-L1-Ar1-L2-Y genel formül (I)'e ait fizyolojik açidan aktif bilesiklerle; ve ilgili N-oksitlerle, ve bunlarin ön ilaçlariyla; ve bu gibi bilesiklerin ve bunlarin N-oksitlerinin ve ön ilaçlarinin farmasötik açidan kabul gören tuzlari ve solvatlariyla (örn., hidratlar) ilgilidir. Bu bilesikler, degerli farmasötik özelliklere,özellikle de VCAM-1 ve fibronektinin integrin VLA-4 (alfa4 beta1) ile etkilesimini düzenleyebilme kabiliyetine sahiptir.
TR2001/02959T 1999-04-12 2000-04-12 İntegrin antagonistleri olarak ikame edilmiş bisiklik heteroaril bileşikleri TR200102959T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9908355.2A GB9908355D0 (en) 1999-04-12 1999-04-12 Chemical compounds
US14147099P 1999-06-29 1999-06-29

Publications (1)

Publication Number Publication Date
TR200102959T2 true TR200102959T2 (tr) 2002-04-22

Family

ID=26315408

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02959T TR200102959T2 (tr) 1999-04-12 2000-04-12 İntegrin antagonistleri olarak ikame edilmiş bisiklik heteroaril bileşikleri

Country Status (24)

Country Link
US (1) US6706738B2 (tr)
EP (1) EP1183254B1 (tr)
KR (1) KR20010110750A (tr)
CN (1) CN1350534A (tr)
AT (1) ATE286896T1 (tr)
AU (1) AU769554B2 (tr)
BG (1) BG106083A (tr)
BR (1) BR0010599A (tr)
CA (1) CA2369728A1 (tr)
CZ (1) CZ20013661A3 (tr)
DE (1) DE60017389T2 (tr)
EE (1) EE200100528A (tr)
ES (1) ES2231179T3 (tr)
HK (1) HK1044937A1 (tr)
HR (1) HRP20010732A2 (tr)
HU (1) HUP0200803A3 (tr)
IL (2) IL145748A0 (tr)
MX (1) MXPA01010231A (tr)
NO (1) NO20014951L (tr)
NZ (1) NZ514602A (tr)
PL (1) PL351433A1 (tr)
SK (1) SK14372001A3 (tr)
TR (1) TR200102959T2 (tr)
WO (1) WO2000061580A1 (tr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2290403C2 (ru) 2000-12-28 2006-12-27 Дайити Фармасьютикал Ко., Лтд. Ингибиторы vla-4
DK1499311T3 (da) * 2002-03-29 2010-03-08 Novartis Vaccines & Diagnostic Substituerede benzaboler og anvendelse deraf som RAF-kinaseinhibitorer
CA2770493A1 (en) 2003-07-24 2005-02-03 Daiichi Pharmaceutical Co., Ltd. Cyclohexanecarboxylic acid compound
EP1711495A2 (en) 2004-01-23 2006-10-18 Amgen Inc. Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer
UA86614C2 (ru) 2004-01-23 2009-05-12 Амген Инк Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
CN101039652A (zh) * 2004-08-16 2007-09-19 宝洁公司 2－(氨基或取代的氨基)－5,6－取代的苯酚化合物，包含该化合物的染料组合物以及它们的应用
DE102004041137A1 (de) * 2004-08-25 2006-03-02 Wella Ag o-Aminophenol-Derivate und diese Verbindungen enthaltende Färbemittel
US7235688B1 (en) 2004-11-04 2007-06-26 University Of Notre Dame Du Lac Process for preparing histone deacetylase inhibitors and intermediates thereof
US20070021612A1 (en) * 2004-11-04 2007-01-25 University Of Notre Dame Du Lac Processes and compounds for preparing histone deacetylase inhibitors and intermediates thereof
AU2005312048B2 (en) 2004-11-30 2012-08-02 Amgen Inc. Quinolines and quinazoline analogs and their use as medicaments for treating cancer
US7514460B2 (en) 2004-12-22 2009-04-07 4Sc Ag Benzazole analogues and uses thereof
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
TW200804345A (en) 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
RS56600B1 (sr) 2006-04-19 2018-02-28 Novartis Ag 6-o-supstituisana jedinjenja benzoksazola i benzotiazola i postupci inhibicije csf-1r signalinga
US7931838B2 (en) * 2006-08-31 2011-04-26 Virginia Tech Intellectual Properties, Inc. Method for making oriented single-walled carbon nanotube/polymer nano-composite membranes
US7795254B2 (en) * 2007-10-29 2010-09-14 Amgen Inc. Benzomorpholine derivatives and methods of use
UY32138A (es) * 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
UY32470A (es) 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
US8759537B2 (en) 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
US8674113B2 (en) 2010-12-10 2014-03-18 Boehringer Ingelheim International Gmbh Compounds
US8486968B2 (en) 2010-12-10 2013-07-16 Boehringer Ingelheim International Gmbh Compounds
US8466186B2 (en) 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
CA2949215C (en) 2014-05-16 2023-03-14 Protagonist Therapeutics, Inc. .alpha.4.beta.7 integrin thioether peptide antagonists
EP4378536A3 (en) 2014-07-17 2024-10-09 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
EP3201217A4 (en) 2014-10-01 2018-07-18 Protagonist Therapeutics Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
SG11201702553RA (en) 2014-10-01 2017-04-27 Protagonist Therapeutics Inc NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2017117411A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
CN115925790A (zh) 2016-03-23 2023-04-07 领导医疗有限公司 用于合成α4β7肽拮抗剂的方法
EP4092038A1 (en) 2017-09-11 2022-11-23 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
CA3089868A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
US12415816B2 (en) 2018-11-07 2025-09-16 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
KR20220044277A (ko) 2019-07-10 2022-04-07 프로타고니스트 테라퓨틱스, 인코포레이티드 인터루킨-23 수용체의 펩티드 억제제 및 염증성 질환을 치료하기 위한 이의 용도
WO2021146454A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2021146441A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
EP4146639A1 (en) 2020-05-06 2023-03-15 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
EP4247403A4 (en) 2020-11-20 2024-12-11 JANSSEN Pharmaceutica NV COMPOSITIONS OF PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR
TW202241889A (zh) 2020-12-23 2022-11-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑
JP2024525732A (ja) 2021-07-14 2024-07-12 ヤンセン バイオテツク，インコーポレーテツド インターロイキン－２３受容体の脂質化ペプチド阻害剤
JP7782035B2 (ja) 2021-11-09 2025-12-08 エイジャックス セラピューティクス， インコーポレイテッド Ｊａｋ２阻害剤としての６－ヘテロアリールオキシベンゾイミダゾール及びアザベンゾイミダゾール
WO2023086320A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of jak2

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU702487B2 (en) * 1995-08-30 1999-02-25 G.D. Searle & Co. Meta-guanidine, urea, thiourea or azacyclic amino benzoic acid derivatives as integrin antagonists
JP2002511462A (ja) * 1998-04-10 2002-04-16 ジー・ディー・サール・アンド・カンパニー ビトロネクチンアンタゴニストとしてのヘテロ環式グリシルβ−アラニン誘導体
DK1153017T3 (da) * 1999-02-16 2006-07-17 Aventis Pharma Ltd Bicykliske forbindelser og deres anvendelse som integrinreceptorligander

Also Published As

Publication number Publication date
DE60017389D1 (de) 2005-02-17
NO20014951D0 (no) 2001-10-11
EP1183254B1 (en) 2005-01-12
HUP0200803A3 (en) 2002-12-28
PL351433A1 (en) 2003-04-22
WO2000061580A1 (en) 2000-10-19
AU3981600A (en) 2000-11-14
IL145748A0 (en) 2002-07-25
HK1044937A1 (zh) 2002-11-08
NZ514602A (en) 2003-06-30
HRP20010732A2 (en) 2002-12-31
CA2369728A1 (en) 2000-10-19
US20020173506A1 (en) 2002-11-21
SK14372001A3 (sk) 2002-06-04
US6706738B2 (en) 2004-03-16
MXPA01010231A (es) 2003-07-21
DE60017389T2 (de) 2006-03-02
IL145748A (en) 2007-02-11
BR0010599A (pt) 2002-02-13
CZ20013661A3 (cs) 2002-01-16
KR20010110750A (ko) 2001-12-13
EP1183254A1 (en) 2002-03-06
ES2231179T3 (es) 2005-05-16
CN1350534A (zh) 2002-05-22
NO20014951L (no) 2001-12-11
HUP0200803A2 (hu) 2002-07-29
AU769554B2 (en) 2004-01-29
ATE286896T1 (de) 2005-01-15
EE200100528A (et) 2003-02-17
BG106083A (en) 2002-05-31

Similar Documents

Publication Publication Date Title
TR200102959T2 (tr) İntegrin antagonistleri olarak ikame edilmiş bisiklik heteroaril bileşikleri
TR200100588T2 (tr) Hücre yapışmasının önlenmesini modüle eden aza-bisikleler.
PL315035A1 (en) Cyclic amide derivatives as antagonistic substances in respect to neurokinin a
TR200102489T2 (tr) 3-Fenilpiridin Türevleri ve bunların NK-1 alıcı antagonistler olarak kullanılması
CA2303848A1 (en) Substituted anilides
MY124390A (en) Substituted bicyclic derivatives useful as anticancer agents
AU2003301020A1 (en) Isoquinolinone derivatives and their use as therapeutic agents
BG66085B1 (bg) Фенилаланинови производни
TR200101398T2 (tr) Pirolidin türevleri-CCR-3 reseptörü antagonistleri.
TR200000520A2 (tr) 4-Fenil-piridin türevleri.
MXPA03008215A (es) Inhibidores de integrina alfa v beta 6.
ES2139760T3 (es) Nuevas lactamas sustituidas con 4-piperidinilo con propiedades antagonistas del receptor de neurokinina 2 en el tratamiento del asma.
MXPA04000278A (es) Uso de antagonistas del receptor nk-1 con estructura piridinica para tratamiento de lesiones cerebrales, espinales o neuronales.
ATE377602T1 (de) Morphinanderivate und ihre medizinische anwendung
DE60027700D1 (de) Bicyclische verbindungen und ihre verwendung als integrinrezeptorliganden
TR199902848T2 (tr) Ergolin türevleri ve bunlarin somatostatin reseptör antagonist olarak kullanimlari
DK0733051T3 (da) Bicykliske, heterocykliske forbindelser som neurokinin A-antagonister
WO2002036553A3 (en) Substituted alkanoic acids
DE69829215D1 (de) Substituierte beta-alaninen
WO2001064659A3 (en) Indane derivatives and their use as cell adhesion inhibitors
WO2001029066A3 (en) Basic monocyclic compounds having nk2 antagonist action, processes for their preparation, and formulations containing them
MXPA02012015A (es) Ligandos de receptores para integrinas.
EA200300226A1 (ru) ГЕМ-ЗАМЕЩЕННЫЕ АНТАГОНИСТЫ ИНТЕГРИНА αvβ3
TR200100354T2 (tr) NK-2 Antagonist hareketine sahip monosiklik bileşimler ve oluşumlar.
TR199900013T2 (tr) Yeni bilesikler.